The DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index.
Clinical Features of Adrenocortical Carcinoma, Prognostic Factors, and the Effect of Mitotane Therapy
Open accessAbstract
Adrenocortical carcinoma is a rare tumor, and only limited information is available about its natural history and the effects of therapy. We studied 105 patients (75 female and 30 male; mean age, 46 years) with adrenocortical carcinoma who were referred to us between 1963 and 1987. The average duration of symptoms before diagnosis was 8.7 months. At the time of diagnosis, 68 percent of the patients had endocrine symptoms, and 30 percent had distant metastases. Hormonal studies showed that 79 percent of the tumors were functional. Eighty patients underwent surgery, and 59 also received the adrenal cytotoxic agent mitotane. The median disease-free interval after surgery was 12.1 months (range, 1 to 175). Tumor dissemination occurred in 82 percent of the patients, most commonly to the lung, liver, and adjacent organs. The median survival time was 14.5 months (range, less than 1 to 175), and the five-year survival was 22 percent. Age over 40 years and the presence of metastases at the time of diagnosis were the only factors recognized as indicating a poor prognosis. Mitotane controlled hormonal secretion in 75 percent of the patients. Eight mitotane-treated patients had partial tumor regression, but the drug did not have a significant effect on survival. We conclude that adrenocortical carcinoma carries a poor prognosis. Mitotane therapy may offer transient benefits, particularly in controlling endocrine symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is in accordance with a median age of 46 years in a large single center series in France (10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“In the adult as well as in the pediatric population, there is a predilection for the female gender (the ratio of female to male ranges from 1.5–2.5:1) (10, 17).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“A role of estrogens has also been suggested by the observation of a probable relative increase of diagnosis of ACC during pregnancy (10, 19).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“For 40% to 60% of patients, the major presenting complaints are symptoms and signs of hormone excess (3, 9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Another third present with nonspecific symptoms due to local tumor growth, such as abdominal or flank pain, abdominal fullness, or early satiety (9, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Patients with ACC only rarely present with classical tumor symptoms, such as cachexia or night sweats (3, 10).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Biochemically or clinically apparent adrenocortical hormone production is evident in up to 45% to 70% (9, 10, 85).”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
In the citing paper
“Hypercortisolism is the most common presentation of patients presenting with hormone excess (50%–80% of hormone-secreting ACCs), causing classic symptoms including plethora, diabetes mellitus, muscle weakness/atrophy, and osteoporosis.”
From Adrenocortical carcinoma (2014) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Murphy, B. E. P. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-7-973 · Cited by 1,998
Incidence of malignant tumors in U.S. children
Young, J. L., & Miller, R. W. (1975) · The Journal of Pediatrics · doi:10.1016/s0022-3476(75)80484-7 · Cited by 842
On Distribution-Free Tests for Equality of Survival Distributions
Tarone, R. E., & Ware, J. S. (1977) · Biometrika · doi:10.1093/biomet/64.1.156 · Cited by 733
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Rubinstein, L. J., Herman, M. M., Long, T. F., & Wilbur, J. R. (1975) · Cancer · doi:10.1002/1097-0142(197502)35:2 · Cited by 383
Results of Treatment in 108 Patients with Cushing's Syndrome
Orth, D. N., & Liddle, G. W. (1971) · New England Journal of Medicine · doi:10.1056/nejm197107292850501 · Cited by 327
Research works printed but not linked: 21
- Plager, 1984, Int Adv Surg Oncol, 7, 329
- Macfarlane, 1958, Ann R Coll Surg Engl, 23, 155
- Heinbecker, 1957, Surg Gynecol Obstet, 105, 21
- Brennan, 1987, CA, 37, 348
- Bradley, 1975, Surg Gynecol Obstet, 141, 507
- Greenberg, 1978, Am Surg, 44, 81
- Ostuni, 1975, Arch Intern Med, 135, 1257, 10.1001/archinte.1975.00330090129015 · DOI
- Haq, 1980, Cancer Treat Rep, 64, 909
- Bricaire, 1977, Nouv Presse Med, 6, 3650
- Rappaport, 1978, Arch Fr Pediatr, 35, 551
- Levine, 1978, Am J Dis Child, 132, 238
- Lejonc, 1978, Nouv Presse Med, 7, 3147
- Pugeat, 1980, Ann Endocrinol, 41, 107
- Cathelineau, 1980, Ann Endocrinol, 41, 65
- Cassan, 1978, Nouv Presse Med, 7, 2153
- Benaily, 1975, Arch Fr Pediatr, 32, 441
- Cariou, 1982, Nouv Presse Med, 11, 2821
- Charbonnel, 1980, Nouv Presse Med, 9, 239
- Jarabak, 1981, JAMA, 246, 1706, 10.1001/jama.1981.03320150054033 · DOI
- Levy, 1985, Ann Pediatr (Paris), 32, 541
- du Rostu, 1987, Presse Med, 16, 951
Cited by
Sorted by citations
Items 201–300 of 712
Pediatric adrenocortical tumor – review and management update
Balderrama-Brondani, V., & Fragoso, M. C. B. V. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000540 · Cited by 35
Role of bilateral adrenalectomy in Cushing's disease
Favia, G., Boscaro, M., Lumachi, F., & D'Amico, D. F. (1994) · World Journal of Surgery · doi:10.1007/bf00353737 · Cited by 34
Radiofrequency Ablation of Metastatic Lesions in Adrenocortical Cancer
Abraham, J., Fojo, T., & Wood, B. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00028 · Cited by 34
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
Baudin, É., Docao, C., Gicquel, C., Vassal, G., Bachelot, A., Penfornis, A., & Schlumberger, M. J. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf291 · Cited by 33
BENCSIK, Z., Szabolcs, I., Góth, M., VÖRÖS, A., Kaszás, I., Gönczi, J., Kovács, L., Dohán, O., & Szilägyi, G. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb00889.x · Cited by 33
Adrenocortical carcinoma: a literature review
Thampi, A., Shah, E., Elshimy, G., & Correa, R. (2020) · Translational Cancer Research · doi:10.21037/tcr.2019.12.28 · Cited by 32
Suh, I. (2010) · Archives of Surgery · doi:10.1001/archsurg.2009.292 · Cited by 32
Tonic pupils from giant cell arteritis
Foroozan, R. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.510 · Cited by 32
Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders
Kutikov, A., Crispen, P. L., & Uzzo, R. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00057-8 · Cited by 31
Dickson, P. V., Kim, L., Yen, T. W. F., Yang, A. D., Grubbs, E. G., Patel, D., & Solórzano, C. C. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6749-2 · Cited by 32
Malignant endocrine tumors in patients with MEN 1 disease
Dotzenrath, C., Goretzki, P. E., Cupisti, K., Yang, Q., Simon, D., & Röher, H. D. (2001) · Surgery · doi:10.1067/msy.2001.109500 · Cited by 32
Functioning and Nonfunctioning Adrenocortical Carcinoma
Demeure, M. J., & Somberg, L. B. (1998) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30245-x · Cited by 32
Aupetit, B., Battaglia, C., Zenatti, M., Blanchouin-Emeric, N., & Legrand, J. C. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.1.8421100 · Cited by 32
Pharmacological management of Cushing's syndrome: an update
Dang, C. N., & Trainer, P. J. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800020 · Cited by 31
How to Differentiate Benign from Malignant Adrenocortical Tumors?
Viëtor, C. L., Creemers, S. G., van Kemenade, F. J., van Ginhoven, T. M., Hofland, L. J., & Feelders, R. A. (2021) · Cancers · doi:10.3390/cancers13174383 · Cited by 33
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
Bianchini, M., Puliani, G., Chiefari, A., Mormando, M., Lauretta, R., & Appetecchia, M. (2021) · Cancers · doi:10.3390/cancers13195001 · Cited by 34
Enriquez, M. L., Lal, P., Ziober, A. F., Wang, L., Tomaszewski, J. E., & Bing, Z. (2012) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31823605e7 · Cited by 31
The Role of Minimally Invasive Treatments in Surgical Oncology
Choh, M. S., & Madura, J. A. (2009) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.09.017 · Cited by 31
Hatipoglu, B. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23197 · Cited by 18
Experience with the surgical treatment of adrenal cortical carcinoma
Meyer, A. A., Niemann, U., & Behrend, M. (2004) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.01.021 · Cited by 30
Infantile acne as the initial sign of an adrenocortical tumor
Mann, M., Ellis, S. S., & Mallory, S. B. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.028 · Cited by 30
Cushing’s syndrome: an update on current pharmacotherapy and future directions
Creemers, S. G., Hofland, L. J., Lamberts, S. W. J., & Feelders, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1061995 · Cited by 30
Weigand, I., Altieri, B., Lacombe, A. M. F., Basile, V., Kircher, S., Landwehr, L., Schreiner, J., Zerbini, M. C. N., Ronchi, C. L., Megerle, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa293 · Cited by 31
Targeted genomic analysis of 364 adrenocortical carcinomas
Pozdeyev, N. V., Fishbein, L. M., Gay, L. M., Sokol, E. S., Hartmaier, R. J., Ross, J. S., Darabi, S., Demeure, M. J., Kar, A., Foust, L. J., et al. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0040 · Cited by 30
Mendiratta‐Lala, M., Avram, A. M., Turcu, A. F., & Dunnick, N. R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.04.009 · Cited by 29
A new simple HPLC method for measuring mitotane and its two principal metabolites
Francia, S. D., Pirro, E., Zappia, F., Martino, F., Sprio, A. E., Daffara, F., Terzolo, M., Berruti, A., Carlo, F. D., & Ghezzo, F. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.04.005 · Cited by 29
Aktuelle TNM-Klassifikationssysteme für das Nebennierenkarzinom
Faßnacht, M., Wittekind, C., & Allolio, B. (2010) · Der Pathologe · doi:10.1007/s00292-010-1306-1 · Cited by 29
Cancer of the Endocrine System
Lal, G., O’Dorisio, T. M., McDougall, I. R., & Weigel, R. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50079-8 · Cited by 29
Ilias, Ι., Alevizaki, M. K., Philippou, G., Anastasiou, E., & Souvatzoglou, A. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343888 · Cited by 29
Role of Truncated O-GalNAc Glycans in Cancer Progression and Metastasis in Endocrine Cancers
Pinto, D., & Parameswaran, R. (2023) · Cancers · doi:10.3390/cancers15133266 · Cited by 28
Midan, H. M., Helal, G. K., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Abdelmaksoud, N. M., Mageed, S. S. A., Elballal, M. S., Zaki, M. B., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154690 · Cited by 28
Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line
Fallo, F., Pilon, C., Barzon, L., Pistorello, M., Fagotto, U., Altavilla, G., Boscaro, M., & Sonino, N. (1996) · Endocrine Research · doi:10.1080/07435809609043766 · Cited by 28
Incidentally found adrenocortical carcinoma. A study of 21 patients
Kasperlik-Zaluska, A. A., Migdalska, B. M., & Makowska, A. M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00170-1 · Cited by 28
Chukkalore, D., MacDougall, K. N., Master, V. A., Bilen, M. A., & Nazha, B. (2024) · The Oncologist · doi:10.1093/oncolo/oyae029 · Cited by 29
Gicquel, C., Baudin, É., Bouc, Y. L., & Schlumberger, M. J. (1997) · Annals of Oncology · doi:10.1023/a:1008257530919 · Cited by 27
Fallo, F., Pilon, C., Barzon, L., Pistorello, M., Pagotto, U., Altavilla, G., Boscaro, M., & Sonino, N. (1998) · Chemotherapy · doi:10.1159/000007104 · Cited by 27
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00092-x · Cited by 29
Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature
Wang, W., Han, R., Ye, L., Xie, J., Tao, B., Sun, F., Zhuo, R., Chen, X., Deng, X., Ye, C., et al. (2019) · Endocrine Connections · doi:10.1530/ec-18-0526 · Cited by 29
Cutaneous angiosarcoma of the eyelids
Conway, R. M. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.514 · Cited by 26
Levels of 5-hydroxymethyl-2′-deoxyuridine in DNA from blood as a marker of breast cancer
Djurić, Z., Heilbrun, L. K., Simon, M. S., Smith, D. W., Luongo, D. A., LoRusso, P. M., & Martino, S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960215)77:4 · Cited by 60
Management of adrenal neoplasms
Pommier, R. F., & Brennan, M. F. (1991) · Current Problems in Surgery · doi:10.1016/0011-3840(91)90032-k · Cited by 26
Dick, A. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.518-a · Cited by 26
Combined Liver and Inferior Vena Cava Resection for Adrenocortical Carcinoma
Ohwada, S., Izumi, M., Tanahashi, Y., Kawate, S., 浜田, 邦., Tsutsumi, H., Horiguchi, J., Koibuchi, Y., Takahashi, T., & Yamada, M. (2007) · Surgery Today · doi:10.1007/s00595-006-3404-5 · Cited by 25
Clinical and imaging overview of functional adrenal neoplasms
Low, G., & Sahi, K. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03014.x · Cited by 25
Adrenal Hyperandrogenism in Children
Ghizzoni, L. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.12.4431 · Cited by 25
SEAL, D. V. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.516 · Cited by 25
Growth hormone, insulin, and somatostatin therapy of cancer cachexia
Bartlett, D. L., Torosian, M. H., & Charland, S. L. (1994) · Cancer · doi:10.1002/1097-0142(19940301)73:5 · Cited by 40
Stratakis, C. A., & Chrousos, G. P. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70113-4 · Cited by 25
Medical Therapy for Cushing’s Syndrome in the Twenty-first Century
Tritos, N. A., & Biller, B. M. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.01.006 · Cited by 24
Adrenocortical carcinoma presenting as varicocele and renal vein thrombosis: a case report
Cheungpasitporn, W., Horne, J. M., & Howarth, C. B. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-337 · Cited by 24
Sixty Adrenal Masses of Large Dimensions: Hormonal and Morphologic Evaluation
BERNINI, G. P., Miccoli, P., Moretti, A., Vivaldi, M. S., Iacconi, P., & Salvetti, A. (1998) · Urology · doi:10.1016/s0090-4295(98)00026-0 · Cited by 24
Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma
Clay, M. R., Pinto, E. M., Fishbein, L. M., Else, T., & Kiseljak‐Vassiliades, K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab866 · Cited by 24
Feingold, P. L., Kwong, M. L. M., Sabesan, A. C., Sorber, R. A., & Rudloff, U. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.098 · Cited by 23
Clinical characteristics and prognosis of adrenocortical tumors in children
Wang, Z., Liu, G., Sun, H., Li, K., Dong, K., Ma, Y., & Zheng, S. (2018) · Pediatric Surgery International · doi:10.1007/s00383-018-4409-z · Cited by 25
Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Hescot, S., Körbl, D., Megerle, F., Beuschlein, F., Neu, B., Quinkler, M. O., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0747-5571 · Cited by 23
Screening for primary aldosteronism
Schirpenbach, C., & Reincke, M. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.007 · Cited by 23
Inflammatory optic neuropathy as the presenting feature of herpes simplex acute retinal necrosis
Francis, P. J. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.4.512-a · Cited by 23
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors
For Comete-Cancer Network, Vezzosi, D., Cao, C. D., Hescot, S., Bertherat, J. Y., Haissaguerre, M., Bongard, V., Drui, D., de la Fouchardière, C., Illouz, F., et al. (2017) · Hormones and Cancer · doi:10.1007/s12672-017-0313-6 · Cited by 23
Childhood Adrenocortical Tumours: a Review
Pereira, R. M., DeLacerda, L., Lacerda, H. M., Michalkiewicz, E., Sandrini, F., & Sandrini, R. (2006) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-4-2-81 · Cited by 22
Surgical Management of Adrenocortical Carcinoma
Ranvier, G. G. F., & Inabnet, W. B. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.008 · Cited by 22
Surgical Outcome of Stage III and IV Adrenocortical Carcinoma
Ohwada, S., Izumi, M., Kawate, S., 浜田, 邦., Toya, H., Togo, N., Horiguchi, J., Koibuchi, Y., Takahashi, T., & Yamada, M. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl127 · Cited by 22
Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide
on behalf of the German Adrenocortical Carcinoma Study Group, Kroiß, M., Deutschbein, T., Schlötelburg, W., Ronchi, C. L., Neu, B., Müller, H., Quinkler, M. O., Hahner, S., Heidemeier, A., et al. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0260-7 · Cited by 22
Scintigraphic patterns of adrenocortical carcinoma: morpho-functional correlates
Barzon, L., Zucchetta, P., Boscaro, M., Marzola, M., Bui, F., & Fallo, F. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450743 · Cited by 22
Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma
Papewalis, C., Faßnacht, M., Willenberg, H. S., Domberg, J., Fenk, R. R., Rohr, U., Schinner, S., Bornstein, S. R., Scherbaum, W. A., & Schott, M. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02576.x · Cited by 22
Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
Stigliano, A., Cerquetti, L., Sampaoli, C., Bucci, B., & Toscano, V. (2012) · Journal of Oncology · doi:10.1155/2012/408131 · Cited by 19
The Immunotherapy Landscape in Adrenocortical Cancer
Pegna, G. J., Roper, N., Kaplan, R. N., Bergsland, E. K., Kiseljak‐Vassiliades, K., Habra, M. A., Pommier, Y. G., & Rivero, J. D. (2021) · Cancers · doi:10.3390/cancers13112660 · Cited by 22
Mouse models of adrenocortical tumors
Basham, K. J., Hung, H. A., Lerário, A. M., & Hammer, G. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.031 · Cited by 20
Emerging Therapy for Adrenocortical Carcinoma
Aufforth, R., & Nilubol, N. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.13 · Cited by 20
Picard, C., Faure‐Conter, C., Leblond, P., Brugières, L., Thomas‐Teinturier, C., Hameury, F., Defachelles, A. S., Verschuur, A. C., Brisse, H. J., Sarnacki, S., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28086 · Cited by 20
Tanaka, M., Izeki, M., Miyazaki, Y., Horigome, M., Yoneda, T., 露木, 静., Takami, S., & Aiba, M. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.967 · Cited by 20
Corticosurrénalomes de l'enfant: analyse rétrospective de 54 cas
Teinturier, C., Brugières, L., Lemerle, J., Chaussain, J., & Bougneres, P. F. (1996) · Archives de Pédiatrie · doi:10.1016/0929-693x(96)81300-5 · Cited by 20
Uneventful Pregnancy in an Acromegalic Patient Treated with Slow-Release Lanreotide: A Case Report
De Menis, E. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1489 · Cited by 20
Bachelot, A., Lapoirie, M., Dulon, J., Leban, M., Renard Penna, R., & Touraine, P. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-0787 · Cited by 19
Key MicroRNA’s and Their Targetome in Adrenocortical Cancer
Chehade, M., Bullock, M., Glover, A. R., Hutvágner, G., & Sidhu, S. B. (2020) · Cancers · doi:10.3390/cancers12082198 · Cited by 20
Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors
Drougat, L., Omeiri, H., Lefèvre, L., & Ragazzon, B. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00096 · Cited by 19
Choi, Y. M., Kwon, H., Jeon, M. J., Sung, T., Hong, S. J., Kim, T. Y., Kim, W. B., Shong, Y. K., Lee, J., Song, D. E., et al. (2016) · Medicine · doi:10.1097/md.0000000000003736 · Cited by 19
Adrenocortical Cancer Treatment
Long, S. E., & Miller, B. S. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.04.012 · Cited by 18
Lyraki, R., Grabek, A., Tison, A., Arachchige, L. C. W., Peitzsch, M., Bechmann, N., Youssef, S. A., de Bruin, A., Bakker, E. R. M., Claessens, F., et al. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050053 · Cited by 19
Androgen- and Estrogen-Secreting Adrenal Cancers
Cavlan, D., Bharwani, N., & Grossman, A. B. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.10.016 · Cited by 19
Barzon, L., Fallo, F., & Sonino, N. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5625-3 · Cited by 19
Steroid biosynthesis inhibitors in Cushing's syndrome
Engelhardt, D. (1994) · Journal of Molecular Medicine · doi:10.1007/bf00207474 · Cited by 19
Epidemiology of Adrenocortical Carcinoma
Faßnacht, M., & Allolio, B. (2009) · Springer eBooks · doi:10.1007/978-0-387-77236-3_3 · Cited by 18
Hamanaka, W., Yoneda, S., Shirakusa, T., Shirahama, H., Tashiro, Y., Iwasaki, A., Shiraishi, T., & Tsuru, H. (2008) · Surgery Today · doi:10.1007/s00595-007-3610-9 · Cited by 18
Functioning Adrenocortical Tumors in Children-Secretory Behavior
Mirsaeid, G. A. A., Djafar, M. I., Salehian, M. T., Amirbaigloo, A., Khandan, Z., Jafari, B., & Farzaneh, R. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.835 · Cited by 18
Telomerase activity in the differentiation of benign and malignant adrenal tumors
Teng, L., Tucker, O., Malchoff, C. D., Vaughan, E. D., Jacobson, J., & Fahey, T. J. (1998) · Surgery · doi:10.1067/msy.1998.92172 · Cited by 18
The management of Cushing's disease - from investigation to treatment.
Juszczak, A., & Grossman, A. B. (2013) · PubMed · Cited by 17
Cheng, Y., Kou, W., Zhu, D., Yu, X., & Zhu, Y. T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.811293 · Cited by 18
Preclinical Models of Adrenocortical Cancer
Sedlack, A. J. H., Hatfield, S. J., Kumar, S., Arakawa, Y., Roper, N., Sun, N.-Y., Nilubol, N., Kiseljak‐Vassiliades, K., Hoang, C. D., Bergsland, E. K., et al. (2023) · Cancers · doi:10.3390/cancers15112873 · Cited by 17
Laparoscopic Adrenalectomy for Cancer
Creamer, J., & Matthews, B. D. (2012) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2012.08.006 · Cited by 17
Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey
Lim, J. S., Lee, S., Kim, J. H., Kim, J. H., & _, _. (2020) · Endocrine Connections · doi:10.1530/ec-20-0196 · Cited by 17
Balderrama-Brondani, V., Lacombe, A. M. F., Mariani, B. M. P., Montenegro, L. R., Soares, I. C., Neto, J. E. B., Tanno, F. Y., Srougi, V., Chambo, J. L., Mendonca, B. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031238 · Cited by 17
Boilève, A., Mathy, E., Roux, C., Faron, M., Hadoux, J., Tselikas, L., Ghuzlan, A. A., Hescot, S., Leboulleux, S., de Baère, T., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab449 · Cited by 17
Xenograft models for preclinical drug testing: Implications for adrenocortical cancer
Luconi, M., & Mannelli, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.043 · Cited by 17
Adrenocortical carcinoma – our experience with 11 cases
Langer, P., Bartsch, D. K., Moebius, E., Rothmund, Μ., & Nies, C. (2000) · Langenbeck s Archives of Surgery · doi:10.1007/s004230000151 · Cited by 17
Berruti, A., Terzolo, M., Paccotti, P., Veglio, F., Pia, A. R., Dogliotti, L., & Angeli, A. (1992) · Tumori Journal · doi:10.1177/030089169207800512 · Cited by 17
Yousaf, A., Patterson, J., Hobbs, G. R., Davis, S. M., Yousaf, M., Hafez, M., Albandar, H. J., Hogan, T. F., & Kolodney, J. A. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100206 · Cited by 16
Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
Rossini, E., Giacopuzzi, E., Gangemi, F., Tamburello, M., Cosentini, D., Abate, A., Laganà, M., Berruti, A., Grisanti, S., & Sigala, S. (2021) · Biomedicines · doi:10.3390/biomedicines9060681 · Cited by 16
Adrenocortical carcinoma: What the surgeon needs to know. Case report and literature review
Benassai, G., Desiato, V., Benassai, G., Bianco, T., Sivero, L., Compagna, R., Vigliotti, G., Limite, G., Amato, B., & Quarto, G. (2014) · International Journal of Surgery · doi:10.1016/j.ijsu.2014.05.030 · Cited by 16
Medical Management of Cushing Disease
Tritos, N. A., & Biller, B. M. K. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.05.007 · Cited by 16
Adrenal disorders in pregnancy, labour and postpartum – an overview
Manoharan, M., Sinha, P., & Sibtain, S. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1648395 · Cited by 17
Metadata
- Authors
- Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., Bonnin, A., & Bricaire, H.
- Affiliations
- Hôpital Cochin (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-04-26
- Volume
- 322
- Issue
- 17
- Pages
- 1195-1201
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2336089418
- Cited by
- 717
- References
- 67
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 15 · 2023: 26 · 2022: 22 · 2021: 31 · 2020: 20 · 2019: 17 · 2018: 23 · 2017: 16 · 2016: 19 · 2015: 27 · 2014: 25 · 2013: 19 · 2012: 31
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- adrenocortical carcinoma, mitotane, prognostic factors, adrenal surgery, metastasis, survival, endocrine symptoms, tumor regression, adrenocortical function, age over 40
- MeSH terms
- Adrenal Cortex Hormones, Adrenal Cortex Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitotane, Neoplasm Metastasis, Prognosis, Retrospective Studies, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
